

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7731581

<b>SUBMISSION TYPE:</b>	RESUBMISSION
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>RESUBMIT DOCUMENT ID:</b>	507575014

**CONVEYING PARTY DATA**

Name	Execution Date
DR. LARS HOLTEN-ANDERSEN	06/06/2019
DR. VIBEKE MILLER BREINHOLT	04/04/2019
DR. KENNETT SPROGØE	04/04/2019

**RECEIVING PARTY DATA**

<b>Name:</b>	ASCENDIS PHARMA A/S
<b>Street Address:</b>	TUBORG BOULEVARD 5
<b>City:</b>	HELLERUP
<b>State/Country:</b>	DENMARK
<b>Postal Code:</b>	2900

**PROPERTY NUMBERS Total: 1**

Property Type	Number
<b>Application Number:</b>	16338185

**CORRESPONDENCE DATA****Fax Number:** (704)444-1111*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Phone:** 650-838-2000**Email:** michael.denham@alston.com**Correspondent Name:** ALSTON & BIRD LLP**Address Line 1:** ONE SOUTH AT THE PLAZA, SUITE 4000**Address Line 2:** 101 SOUTH TRYON STREET**Address Line 4:** CHARLOTTE, NORTH CAROLINA 28280-4000

<b>ATTORNEY DOCKET NUMBER:</b>	065588/570454
<b>NAME OF SUBMITTER:</b>	JOE LIEBESCHUETZ
<b>SIGNATURE:</b>	/Joe Liebeschuetz/
<b>DATE SIGNED:</b>	01/09/2023

**Total Attachments: 3**source=2023-01-09 2022-10-24 570454US Inventors to Ascendis Pharma AS\_rescanned assignment#page1.tif  
source=2023-01-09 2022-10-24 570454US Inventors to Ascendis Pharma AS\_rescanned assignment#page2.tif



**ASSIGNMENT**

WHEREAS, the undersigned Inventor(s) (hereinafter referred to as Assignor) has invented the invention described in the patent application entitled **Combination Therapy with Controlled-Release CNP Agonists** that was filed in the United States Patent and Trademark Office on **March 29, 2019**, and was assigned application serial no. **16/338,185**, and is/are the owner(s) of the same and any and all United States Letters Patent to be obtained therefrom (hereinafter referred to as Invention);

AND WHEREAS, **Ascendis Pharma A/S**, having an address of **Tuborg Boulevard 5, 2900 Hellerup, Denmark**, (hereinafter referred to as Assignee) is desirous of acquiring the entire right, title, and interest in and to said Invention;

NOW, THEREFORE, for good and valuable consideration, the receipt for and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign, transfer, and set over unto said Assignee, and Assignee's legal representatives, successors, and assigns, the entire right, title, and interest in and to said Invention, including any continuations, continuations-in-part, divisions, reissues, re-examinations, or extensions thereof, including any and all patents of the United States and foreign countries that may be issued for said Invention;

UPON SAID CONSIDERATIONS, Assignor hereby agrees with Assignee that Assignor will not execute any writing or do any act whatsoever conflicting with these presents;

FURTHERMORE, Assignor covenants that Assignor will, at any time upon Assignee's request, without further or additional consideration but at the expense of said Assignee, execute such additional assignments and other writings, and do such additional acts as said Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and will render all necessary assistance in making application for and obtaining original, divisional, continuation, continuation-in-part, reexamined, reissued, or extended Letters Patent of the United States or of any and all foreign countries on said Invention, and in enforcing any rights or causes of action accruing as a result of such applications or patents, including giving testimony in any proceedings or transactions involving such applications or patents, and executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind and inure to the benefit of the assigns and legal representatives of Assignor and Assignee.

Dr. Lars Holten-Andersen

Inventor

Date

*[Handwritten Signature]*

06.06.2019

Signature of Witness

Printed Name of Witness

Date

*[Handwritten Signature]*

*[Handwritten Name]*

26. Jun. 2019

Dr. Vibeke Miller Breinholt

Inventor

Date

01. APR. 2019

Signature of Witness

Printed Name of Witness

Date

*[Handwritten Signature]*

4/4 - 2019

Dr. Kenneth Sprøge

Inventor

Date

4/4/2019

Signature of Witness


Printed Name of Witness

Date

*[Handwritten Signature]*

4/4 - 2019

Michael Wolff Jensen  
Chairman  
Ascendis Pharma A/S



[Assignor Representative Name]


[Assignor Representative Title]

Ascendis Pharma A/S

Date: 27/6/2019



Signature of Witness



Printed Name of Witness

Date: 07/06/2019